Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Aedes aegypti | Ecdysone receptor | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Brugia malayi | ecdysteroid receptor | Get druggable targets OG5_134445 | All targets in OG5_134445 |
Onchocerca volvulus | Bile acid receptor homolog | Get druggable targets OG5_134445 | All targets in OG5_134445 |
Loa Loa (eye worm) | hypothetical protein | Get druggable targets OG5_134445 | All targets in OG5_134445 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Leishmania major | trypanothione reductase | 0.0046 | 0.1649 | 1 |
Plasmodium vivax | thioredoxin reductase, putative | 0.0046 | 0.1649 | 1 |
Giardia lamblia | NADH oxidase lateral transfer candidate | 0.0016 | 0 | 0.5 |
Mycobacterium tuberculosis | NADPH-dependent mycothiol reductase Mtr | 0.0046 | 0.1649 | 0.2985 |
Mycobacterium tuberculosis | Probable nitrite reductase [NAD(P)H] large subunit [FAD flavoprotein] NirB | 0.0104 | 0.4881 | 0.8837 |
Loa Loa (eye worm) | RNA binding protein | 0.0066 | 0.2781 | 0.1356 |
Mycobacterium tuberculosis | NAD(P)H quinone reductase LpdA | 0.0116 | 0.5523 | 1 |
Treponema pallidum | NADH oxidase | 0.0016 | 0 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0066 | 0.2781 | 0.3878 |
Mycobacterium tuberculosis | Probable membrane NADH dehydrogenase NdhA | 0.0104 | 0.4881 | 0.8837 |
Chlamydia trachomatis | dihydrolipoyl dehydrogenase | 0.0016 | 0 | 0.5 |
Mycobacterium tuberculosis | Putative ferredoxin reductase | 0.0104 | 0.4881 | 0.8837 |
Plasmodium falciparum | thioredoxin reductase | 0.0046 | 0.1649 | 1 |
Mycobacterium tuberculosis | Dihydrolipoamide dehydrogenase LpdC (lipoamide reductase (NADH)) (lipoyl dehydrogenase) (dihydrolipoyl dehydrogenase) (diaphoras | 0.0116 | 0.5523 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0197 | 1 | 1 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0066 | 0.2781 | 0.1356 |
Trypanosoma brucei | trypanothione reductase | 0.0046 | 0.1649 | 1 |
Plasmodium vivax | glutathione reductase, putative | 0.0046 | 0.1649 | 1 |
Mycobacterium tuberculosis | Probable oxidoreductase | 0.0116 | 0.5523 | 1 |
Brugia malayi | Thioredoxin reductase | 0.0046 | 0.1649 | 0.1649 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0066 | 0.2781 | 0.2781 |
Mycobacterium tuberculosis | Probable NADH dehydrogenase Ndh | 0.0104 | 0.4881 | 0.8837 |
Loa Loa (eye worm) | hypothetical protein | 0.0123 | 0.5918 | 0.5112 |
Echinococcus multilocularis | thioredoxin glutathione reductase | 0.0046 | 0.1649 | 0.5928 |
Loa Loa (eye worm) | TAR-binding protein | 0.0066 | 0.2781 | 0.1356 |
Schistosoma mansoni | tar DNA-binding protein | 0.0066 | 0.2781 | 0.3878 |
Mycobacterium ulcerans | flavoprotein disulfide reductase | 0.0016 | 0 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0066 | 0.2781 | 0.3878 |
Trypanosoma cruzi | trypanothione reductase, putative | 0.0046 | 0.1649 | 1 |
Wolbachia endosymbiont of Brugia malayi | dihydrolipoamide dehydrogenase E3 component | 0.0016 | 0 | 0.5 |
Echinococcus multilocularis | tar DNA binding protein | 0.0066 | 0.2781 | 1 |
Trichomonas vaginalis | mercuric reductase, putative | 0.0016 | 0 | 0.5 |
Mycobacterium leprae | DIHYDROLIPOAMIDE DEHYDROGENASE LPD (LIPOAMIDE REDUCTASE (NADH)) (LIPOYL DEHYDROGENASE) (DIHYDROLIPOYL DEHYDROGENASE) (DIAPHORASE | 0.0116 | 0.5523 | 1 |
Echinococcus granulosus | thioredoxin glutathione reductase | 0.0046 | 0.1649 | 0.5928 |
Trichomonas vaginalis | glutathione reductase, putative | 0.0016 | 0 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0066 | 0.2781 | 0.3878 |
Mycobacterium ulcerans | dihydrolipoamide dehydrogenase | 0.0016 | 0 | 0.5 |
Brugia malayi | glutathione reductase | 0.0046 | 0.1649 | 0.1649 |
Mycobacterium ulcerans | dihydrolipoamide dehydrogenase, LpdB | 0.0016 | 0 | 0.5 |
Echinococcus granulosus | tar DNA binding protein | 0.0066 | 0.2781 | 1 |
Mycobacterium tuberculosis | Probable dehydrogenase | 0.0104 | 0.4881 | 0.8837 |
Onchocerca volvulus | Bile acid receptor homolog | 0.0197 | 1 | 1 |
Mycobacterium tuberculosis | Probable reductase | 0.0104 | 0.4881 | 0.8837 |
Schistosoma mansoni | tar DNA-binding protein | 0.0066 | 0.2781 | 0.3878 |
Loa Loa (eye worm) | hypothetical protein | 0.0123 | 0.5918 | 0.5112 |
Brugia malayi | RNA binding protein | 0.0066 | 0.2781 | 0.2781 |
Brugia malayi | TAR-binding protein | 0.0066 | 0.2781 | 0.2781 |
Plasmodium falciparum | glutathione reductase | 0.0046 | 0.1649 | 1 |
Wolbachia endosymbiont of Brugia malayi | dihydrolipoamide dehydrogenase E3 component | 0.0016 | 0 | 0.5 |
Brugia malayi | hypothetical protein | 0.0123 | 0.5918 | 0.5918 |
Toxoplasma gondii | thioredoxin reductase | 0.0046 | 0.1649 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC50 (functional) | = 0.99 uM | Effective concentration for ecdysone-dependent transactivation in mammalian cell line expressing Aedes aegypti ecdysone receptor | ChEMBL. | 12749904 |
EC50 (functional) | = 0.99 uM | Effective concentration for ecdysone-dependent transactivation in mammalian cell line expressing Aedes aegypti ecdysone receptor | ChEMBL. | 12749904 |
Fold induction (functional) | = 64 | Fold induction of ecdysone-dependent transactivation in mammalian cell line expressing Aedes aegypti ecdysone receptor at 33 uM | ChEMBL. | 12749904 |
Fold induction (functional) | = 64 | Fold induction of ecdysone-dependent transactivation in mammalian cell line expressing Aedes aegypti ecdysone receptor at 33 uM | ChEMBL. | 12749904 |
Rel Max FI (functional) | = 0.42 | Ratio of maximal ecdysone-dependent transactivation in cell line expressing Aedes aegypti ecdysone receptor compared to cpd2 | ChEMBL. | 12749904 |
Rel Max FI (functional) | = 0.42 | Ratio of maximal ecdysone-dependent transactivation in cell line expressing Aedes aegypti ecdysone receptor compared to cpd2 | ChEMBL. | 12749904 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.